Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences. This FOA will fund investigators to develop a larger research project grant application.

LOI: 30 days prior to applicate due date
Deadline: June 15, 2021; November 17, 2021; June 14, 2022; November 17, 2022; June 14, 2023; November 17, 2023

 

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required)
This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.
This FOA is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial must apply to the "Independent Clinical Trial Not Allowed companion FOA (PAR-21-128).

Deadline: Standard dates (June 12, 2021; October 12, 2021; February 12, 2022)

 

The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants proposing a clinical trial, a clinical trial feasibility study, or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOAs (PAR-21-111 or PAR-21-318).

Deadline: Standard dates (June 12, 2021; October 12, 2021; February 12, 2022)

 

Support for Research Excellence – First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)
SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research (see NOT-OD-20-031) with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions.

The purpose of SuRE-First awards is to support research grants for faculty investigators who have not had prior independent external research grants.

Deadline: September 28, 2021; September 28, 2022; September 28, 2023

 

The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required)
This Funding Opportunity Announcement (FOA) represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. This goal is achieved by providing protected time through salary and research support for the initial 3 years of the first independent tenure-track faculty position, or its equivalent, beginning at the time when the candidate starts a tenure-track faculty position.

This FOA is designed specifically for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants planning studies with specific application toward processes or products in mind should submit under the "Independent Clinical Trial Required" companion FOA (PAR-21-111). Applicants not planning an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial or independent basic experimental study with humans, must apply to the "Independent Clinical Trial Not Allowed" companion FOA (PAR-21-128).

Deadline: Standard dates (June 12, 2021; October 12, 2021; February 12, 2022)

DOD FY21 Lung Cancer Research Program (LCRP) Idea Development Award (PDF)
The FY21 LCRP Idea Development Award mechanism promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports conceptually innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress toward eradicating deaths and suffering from lung cancer. Research applications in the area of mesothelioma will not be accepted. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale.

New Investigators: The FY21 LCRP Idea Development Award mechanism encourages applications from independent investigators in the early stages of their careers (i.e., within 10 years of their first faculty appointment or equivalent). The New Investigator category is designed to allow applicants early in their faculty appointments to compete for funding separately from established investigators. Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately. Principal Investigators (PIs) using the New Investigator category are strongly encouraged to strengthen their applications by collaborating with investigators experienced in lung cancer research and/or possessing other relevant expertise. It is the responsibility of the applicant to describe how the included collaboration will augment the PI’s expertise to best address the research question. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

Key elements of this award are as follows:

• Innovation: Research deemed innovative may introduce a new paradigm, challenge current paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities.
• Impact: Research that has high potential impact may lead to major advancements and significantly accelerate progress toward eradicating deaths and suffering from lung cancer

LOI: May 5, 2021
Deadline: July 28, 2021



DOD FY21 Lung Cancer Research Program (LCRP) Investigator-Initiated Translational Research Award (PDF)
The FY21 LCRP Investigator-Initiated Translational Research Award mechanism supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician’s firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science.

This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following:

• Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts
• Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission
• Correlative studies that are associated with an open/ongoing or completed clinical trial and projects that develop endpoints for clinical trials

Preliminary lung cancer relevant data to support the feasibility of the research hypotheses and research approaches are required.

LOI: May 5, 2021
Deadline: July 28, 2021



DOD FY21 Lung Cancer Research Program (LCRP) Clinical Translational Research Partnership Award (PDF)
The FY21 LCRP Clinical Translational Research Partnership Award supports partnerships between clinicians and research scientists that will accelerate the movement of promising ideas in lung cancer into clinical applications. This award supports the development of translational research collaborations between two independent, faculty-level (or equivalent) investigators to address a critical problem or question in lung cancer in a manner that would be less readily achievable through separate efforts. One partner in the collaboration must be a research scientist and the other must be a clinician. In addition, one partner in the collaboration is strongly encouraged to be an active duty Service member or Federal employee from a Department of Defense (DoD) military treatment facility or laboratory, or a Department of Veterans Affairs (VA) medical center or research laboratory. It should be clear that both have had equal intellectual input into the design of the research project. Multi-institutional partnerships are encouraged but not required. At least one member of the partnership must have experience either in lung cancer research or lung cancer patient care. A proposed project in which the clinical partner merely supplies tissue samples or access to patients will not meet the intent of this award mechanism.

This mechanism is intended to support a pilot, proof-of-principle, or early-phase clinical trial and associated correlative science. A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of interventions on biomedical or behavioral health-related outcomes. It is expected that the proposed trial will have a well developed rationale, strong preliminary data, trial methodology, and execution plan. Any proposed preclinical studies in addition to the trial should be appropriately justified as to its necessity to inform and interpret trial results and the correlative science. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) and/or Investigational Device Exemption (IDE) submission, applications must demonstrate availability of, and access to, clinical reagents (e.g., therapeutic molecules) and patient population(s).

Consumer advocate involvement in the application is strongly encouraged. As part of the research team, the consumer advocate would assist in the development of the research question, project design, oversight, recruitment, and evaluation, as well as other significant aspects of the proposed project. As a lay representative, the consumer advocate should be an individual who has been diagnosed with lung cancer and is active in a lung cancer advocacy organization. The consumer advocate role should be focused on providing objective input on the research and its potential impact for individuals with, or at risk for, lung cancer. The success of the project must be supported by the unique skills and contributions of each partner. The proposed study must include clearly stated plans for interactions between the Principal Investigators (PIs) and institutions involved. The plans must include communication, coordination of research progress and results, and data transfer. Additionally, multi-institutional applications must provide an intellectual property plan to resolve potential intellectual and material property issues and to remove institutional barriers that might interfere with achieving high levels of cooperation to ensure the successful completion of this award.

LOI: July 14, 2021
Deadline: July 28, 2021



Development of Animal Models and Related Biological Materials for Research (R21 Clinical Trial Not Allowed)
This funding opportunity announcement (FOA) encourages innovative research to develop, characterize, and improve animal models, biological materials, and novel technologies to better understand human health and disease. This FOA also seeks projects aimed at improving the diagnosis and control of diseases that interfere with animal use for biomedical research. The proposed project must have broad application to multiple NIH Institutes or Centers (ICs) to align with the Office of Research Infrastructure Programs’ (ORIP) trans-NIH mission. The proposed studies must explore multiple body systems or evaluate diseases that impact multiple body systems. Applications that develop models focused on a specific disease or area of research, or only propose studies primarily relevant to a single NIH IC, will be considered not acceptable to this FOA and will be withdrawn.

Deadline: June 16, 2021; October 16, 2021; February 16, 2022; June 16, 2022; October 16, 2022



Medical Scientist Training Program (T32)
The goal of the Medical Scientist Training Program (MSTP) is to develop a diverse pool of highly trained clinician-scientist leaders available to meet the Nation’s biomedical research needs. Specifically, this funding opportunity announcement (FOA) provides support to eligible domestic institutions to develop and implement effective, evidence-informed approaches to integrated dual-degree training leading to the award of both clinical degrees, e.g., MD, DO, DVM, DDS, PharmD, and research doctorate degrees (PhD). With the dual qualification of rigorous scientific research and clinical practice, graduates will be equipped with the skills to develop research programs that accelerate the translation of research advances to the understanding, detection, treatment and prevention of human disease, and to lead the advancement of biomedical research. Areas of particular importance to NIGMS are the iterative optimization of MSTP training efficacy and efficiency, fostering the persistence of MSTP alumni in research careers, and enhancing the diversity of the clinician-scientist workforce. NIGMS expects that the proposed research training programs will incorporate didactic, research, mentoring and career development elements to prepare trainees for careers that will have a significant impact on the health-related research needs of the Nation.

This Funding Opportunity Announcement (FOA) does not allow appointed Trainees to lead an independent clinical trial but does allow them to obtain research experience in a clinical trial led by a mentor or co-mentor.

Deadline: Standard dates (May 25, 2021; September 25, 2021; January 25, 2022)



High-Priority Behavioral and Social Research Networks (R24 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications to develop new research and research infrastructure for life course research on aging; attract new researchers in aging; infuse a focus on health disparities into aging research; and address ongoing needs for harmonization and biomarker collection in large population panel studies, as recommended by the 2019 BSR NACA Review. Network/infrastructure-building activities include, but are not limited to: meetings to develop novel research areas and interact on the development of infrastructure; small-scale pilots; dissemination and outreach activities; and educational activities. NIA seeks to renew critical ongoing network efforts as well as initiate new networks limited to the following priority areas: midlife reversibility of biobehavioral risk associated with early life adversity; harmonization of Health and Retirement Study (HRS) international aging studies; biomarker collection in population studies; and innovation in longitudinal aging studies.

LOI: May 23, 2021
Deadline: June 23, 2021



Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
SuRE is a research capacity building program designed to develop and sustain research excellence in U.S. higher education institutions that receive limited NIH research support and serve students from groups underrepresented in biomedical research NOT-OD-20-031 with an emphasis on providing students with research opportunities and enriching the research environment at the applicant institutions.

The purpose of SuRE awards is to provide research grant support for faculty investigators who have prior experience in leading externally-funded, independent research but are not currently funded by any NIH Research Project Grants with the exception of SuRE or SuRE-First awards.

Deadline: May 26, 2021; May 26, 2022; May 26, 2023



Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Independent Basic Experimental Studies with Humans Required)
The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences.

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA.

The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants planning independent clinical trials with specific application towards processes or with products in mind, must apply to the companion FOA, PAR-21-171. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-21-172.

Deadline: Standard dates (June 12, 2021; October 12, 2021; February 12, 2022)



Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Required)
The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial trial, as part of their research and career development. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants", must apply to companion FOA, PAR-21-170 . Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA, PAR-21-172.

Deadline: Standard dates (June 12, 2021; October 12, 2021; February 12, 2022)



Transition to Independent Environmental Health Research (TIEHR) Career Award (K01 Clinical Trial Not Allowed)
The Transition to Independent Environmental Health (TIEHR) Career Award is a 3-year bridge scholar development program for newly independent faculty who intend to pursue research careers in environmental health sciences. At the conclusion of the career development period the candidates are expected to demonstrate they can successfully compete for research funding in the environmental health sciences.

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA PAR-21-171. Applicants proposing basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants”, should apply to the companion FOA PAR-21-170)

Deadline: Standard dates (June 12, 2021; October 12, 2021; February 12, 2022)



Early-Stage Development of Data Science Technologies for Infectious and Immune-mediated Diseases (U01 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation.

As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.

LOI: 30 days prior to application
Deadline: July 2, 2021; February 17, 2022; July 1, 2022

No current research funding opportunities available.

Notice of Special Interest (NOSI) to add harassment as an area of interest to Research to Understand and Inform Interventions that Promote the Research Careers of Individuals in the Biomedical Sciences

The purpose of this Notice is to inform potential applicants of the NIH’s interest in supporting research on interventions designed to change the culture to mitigate or eliminate sexual harassment in the biomedical research enterprise. This notice aligns with the Anti-Sexual Harassment policy statements released by NIH as well as recommendations made in the December 2019 Report from the Working Group to the Advisory Committee to the NIH Director (ACD)on Changing the Culture to End Sexual Harassment, which were endorsed by the ACD.

Research Objectives

The NIH is encouraging applications to investigate and understand the culture and climate of sexual harassment. The objective of this Notice is to invite applications associated with PAR-19-295 “Research to Understand and Inform Interventions that Promote the Research Careers of Individual in the Biomedical Sciences (R01 – Clinical Trial Not Allowed)”. The FOA encourages the use of evidence-based practices and recognizes the need for more hypothesis-driven research to test biomedical training, mentoring and networking interventions for efficacy and replicability across career stages and at a range of institution types and to provide insights into the factors contributing to success. Through this funding announcement, NIH intends to enhance the evidence base for effective, high-impact, scalable interventions, and to improve an understanding of the factors contributing to success, including the social and behavioral factors involved in the advancement of individuals pursuing independent academic biomedical research careers.

This NOTICE emphasizes an interest in a broad range of research that provides generalizable and reproducible results that could inform interventions to mitigate and eliminate sexual harassment in the biomedical research workforce. NIH defines sexual harassment as “a form of harassment that violates Title VII of the Civil Rights Act of 1964. Unwelcome sexual advances, requests for sexual favors, and other verbal or physical conduct of a sexual nature constitute sexual harassment when this conduct explicitly or implicitly affects an individual's employment, unreasonably interferes with an individual's work performance, or creates an intimidating, hostile, or offensive work environment.” Examples of harassing and threatening conditions or behaviors include, but are not limited to:

• Repeated attempts to establish an unwanted relationship
• Sharing sexually inappropriate images or videos, such as pornography, with others in the workplace
• Sending suggestive letters, notes, texts, or e-mails
• Displaying inappropriate sexual images in the workplace
• Telling lewd jokes or sharing sexual anecdotes
• Making inappropriate sexual gestures
• Staring in a sexually suggestive or offensive manner or inappropriate whistling
• Making sexual comments about appearance, clothing, or body parts
• Inappropriate touching, including pinching, patting, rubbing, or purposefully brushing up against another person
• Making offensive comments about or asking questions about someone's sexual behavior or history, sexual orientation, or gender identity

The NIH is encouraging the community to build a greater understanding of the culture and the environment that may lead to increased risk of sexual harassment, in order to develop interventions or inform existing policies and procedures to help mitigate this risk.

First Available Due Date: October 15, 2021

Organizations with Peer Review Funding Systems  (PDF)

NCI

Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)
This funding opportunity announcement (FOA) encourages applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science.

Deadline: November 8, 2021; March 7, 2022; November 8, 2022; March 7, 2023; November 5, 2023; March 7, 2024

 

Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications to stimulate exploratory research relevant to the mission of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP) using existing (publicly available) biospecimens currently stored in repositories in the United States. This will include, but not be limited to, collections associated with the Population Assessment of Tobacco and Health (PATH) Study, the National Health and Nutrition Examination Survey (NHANES), the National Heart, Lung and Blood Institute’s (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC), and the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Proposed research should seek to maximize the scientific value of these stored collections and to provide researchers with an opportunity to generate preliminary data for subsequent research proposals. Other publicly available datasets would be considered, depending on analyses to be conducted. These applications need to provide justification why the data set is unique, and the research questions cannot be answered from a publicly available, nationally representative, data set.

The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

LOI: 60 days prior to application due date
Deadline: October 8, 2021; August 8, 2022; March 8, 2023

  

Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to invite R21 applications proposing the innovative analysis of existing (publicly available) nationally representative U.S. cross-sectional and longitudinal data, to investigate novel scientific ideas and/or to generate new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP). Other publicly available data sets would be considered depending on the analyses to be conducted; however, nationally representative analyses will receive priority. Applications not using nationally representative data sets will need to provide justification why the data set is unique, and why the research questions cannot be answered from a (publicly available) nationally representative data set. This FOA encourages the analyses of public use datasets that may inform tobacco regulatory actions in the United States (U.S.).

The awards under this FOA will be administered by NIH using funds that have been made available through FDA-CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this FOA are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) - Center for Tobacco Products (CTP).

LOI: 60 days prior to application due date
Deadline: October 8, 2021; August 8, 2022; March 8, 2023 

 

OTHER NIH & FEDERAL AGENCIES

Technologies for Improving Minority Health and Eliminating Health Disparities (R41/R42- Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Technology Transfer (STTR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined health disparity population groups. Appropriate technologies should be effective, affordable, and culturally acceptable.

LOI: April 3, 2021
Deadline: May 3, 2021

  

Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications that propose to develop a product, process or service for commercialization with the aim of improving minority health and/or reducing and ultimately eliminating health disparities in one or more NIH-defined population groups who experience health disparities. Appropriate technologies should be effective, affordable, and culturally acceptable.

LOI: April 3, 2021
Deadline: May 3, 2021

  

AHRQ/PCORI Learning Health System Small Grant Pilot Program (R03)
The Agency for Healthcare Research and Quality (AHRQ), in partnership with the Patient-Centered Outcomes Research Institute (PCORI), invites applications for funding to support innovative patient-centered outcomes research small pilot projects in Learning Health Systems (LHS) that evaluate the outcomes of embedded research and evaluate the processes by which embedded research can enhance impact, stakeholder engagement, and other health system-identified outcomes of interest.

Deadline: Standard dates (June 16, 2021; October 16, 2021; February 16, 2022)

  

HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)
This funding opportunity announcement (FOA) is part of a suite of FOAs to support the development of safe, effective, and non-addictive therapeutics to treat pain. The goal of this FOA is to support team-based research projects to develop assays, screening and early optimization work to develop a non-addictive therapeutic to treat pain. Discovery and validation of pharmacodynamic markers efficacy and pharmacokinetic/pharmacodynamic (PK/PD) studies are also responsive. The result of the project should be to advance a hit or lead to the point where they can meet the entry criteria for RFA-NS-21-010 HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) within the 5 years of the award, there is no opportunity for renewal of this award. Applications should propose a plan that will lead to the development of analgesics with a rigorous biological rationale and scientifically sound assays. If the data does not currently exist, the application must include a strong plan for developing data linking the putative therapeutic target(s) to the proposed pain indication and supporting the hypothesis that altering the target activity will produce desirable outcomes for the disease.

This FOA is not specific for any one or group of pain conditions. Projects to develop therapeutics for acute pain, chronic pain, painful neuropathy, musculoskeletal pain, headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, eye pain, sickle-cell pain, post-surgical pain, cancer pain, visceral pain, post stroke pain, myofascial pain, painful disorders of the orofacial region and other conditions will be considered. Projects to develop analgesics for a combination of chronic overlapping pain conditions or for specific disease or pathological conditions will also be considered. Projects that seek to identify pain treatment targets in specific populations such as women, children, older adults, and other underrepresented groups will also be responsive to this FOA. Input from patients and caregivers on the therapeutic goals of the project is encouraged. The goal of each 5-year U19 application should be to identify candidate therapeutic(s) that will be ready to be submitted to RFA-NS-21-010 for further optimization.

LOI: 30 days prior to application due date
Deadline: April 27, 2021; June 22, 2021; October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; October 10, 2023

  

HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R34 Clinical Trial Not Allowed)
The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R34 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R34 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.

LOI: 30 days prior to application due date
Deadline: April 27, 2021; June 22, 2021; October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; October 10, 2023

  

FOUNDATIONS

Alex's Lemonade Stand 2021 Reach Grant (PDF)
The purpose of the Reach Grant is to advance ALSF’s mission to find cures and better treatments for childhood cancers by providing support to move hypothesis-driven research into the clinic. Significant barriers exist that impede the translation of innovative and important ideas to the clinic. The Reach Grant seeks to remove one of these barriers by providing support for important preclinical projects that are necessary to move a study from the pre-clinical arena into a clinical trial. Thus, the goal of this award is to support selected late-translational studies. Preference will be given to those research projects which, if funded, will likely result in the initiation of a clinical trial in two to three years from the start of the project, by, for example, completing IND-enabling studies, providing requisite preclinical data for clinical trial development, or perhaps through the validation of biomarkers that will enable selection of the correct patients for entry into new clinical trials.

Deadline: March 22, 2021

 

Alex's Lemonade Stand 2021 Crazy 8 Initiative Award Program (PDF)
Alex’s Lemonade Stand Foundation (ALSF) has focused on enhancing collaborations that develop cures since its beginning. As ALSF continues to distinguish itself as a leader in funding childhood cancer research and accelerating cures, the Foundation’s grants have facilitated unprecedented collaborations between the brightest minds in childhood cancer research from around the globe. ALSF launched the Crazy 8 Initiative with the purpose of harnessing that collaborative spirit to detail roadmaps to cures for specific high-risk childhood cancers and to identify and solve critical challenges facing the childhood cancer community. The Crazy 8 Initiative kicked off in 2018 with a meeting that brought together more than 90 top scientists from around the world to contribute their expertise in eight key pediatric oncology disciplines.

Crazy 8 Disciplines:

• Embryonal brain cancers
• High-grade gliomas
• Fusion-positive sarcomas
• Fusion-negative sarcomas
• Leukemias
• Neuroblastoma
• Big data
• Catalyzing clinical trials

The group aimed to undertake the big question: How can we tackle major obstacles impeding progress towards cures for childhood cancer through multidisciplinary collaborative research? The outcomes of the meeting included a list of addressable problems and proposed pathways forward to overcome these obstacles to make cures a reality. The group identified four crosscutting research themes that form the basis of this RFA, with the overarching goal of making a major impact on the field of childhood cancer.

Crazy 8 Research Themes:

• Developmental origins of pediatric cancers
• Drugging currently undruggable pediatric cancer drivers
• Developing novel immunotherapies
• Discovery and development of novel pediatric cancer drug targets

LOI: April 26, 2021
Deadline: August 5, 2021

 

  

NOSI

Notice of Special Interest (NOSI):Understanding and Addressing the Impact of Structural Racism and Discrimination on Biomedical Career Progression and the Biomedical Research Enterprise
The purpose of this Notice of Special Interest (NOSI) is to inform applicants of topic areas of interest to the National Institute of General Medical Sciences (NIGMS) to study and/or address the impacts of structural racism and discrimination on biomedical career progression and the biomedical research enterprise.

NIGMS encourages applications that will examine and/or test interventions to address these factors in the career development of research-oriented individuals in the biomedical sciences, as well as the the systems and processes that organize and sustain the broader biomedical research enterprise. The overall goal of this NOSI is to develop an actionable evidence base to promote inclusion and equity in the biomedical research enterprise; topics of interest include, but are not limited to, studies to understand and/or reduce disparities in: 

• Admissions practices in higher education
• Curricular design and pedagogical methods
• Financing of higher education and impact of student debt on persistence and career progression
• Time to independence and the impacts on persistence across demographic groups 
• Physical spaces in which biomedical research is conducted (e.g., accessibility to scientists with disabilities, inclusive spaces for teaching and learning) 
• Racism, harassment, and discrimination in the research environment and their psychosocial and mental health impacts (e.g., stereotype threat, imposter phenomenon, microaggressions, tokenism, isolation, anxiety, depression)
• Influences of academic culture on career choice and progression;
• The advancement structure for students and postdoctoral scientists within academic biomedical research environments. (e.g., career progression as impacted by power dynamics, the apprentice model, markers of prestige, mentoring, or networks)
• Hiring, tenure And promotion processes of faculty 
• Additional and uncompensated or unrewarded professional service by scientists from underrepresented groups (e.g., “minority or diversity tax”) 
• Institutional resource allocation (e.g., startup packages, physical space, and staff allocation)
• Peer review (e.g., publications, awards, research grants) 
• Practices of funders (e.g., government agencies, private philanthropies)
• Support for commercialization of biomedical discoveries by scientists from underrepresented backgrounds (e.g., Federal Small Business Innovation Research, venture capital investments)

First Available Due Date: May 17, 2021

  

Notice of Special Interest (NOSI): NINR Priority Areas for Training and Career Development Awards
The National Institute of Nursing Research (NINR) is committed to training the next generation of nurse scientists at all levels of education and encouraging training in important new areas of nursing research. NINR is issuing this Notice to highlight interest in receiving grant applications focused in the following area(s):

• Social determinants of health
• Health disparities and health equity
• Community and population health
• Observational and intervention research with practice and policy applications
• Embodiment of social inequalities
• Multilevel approaches bridging biology to society

First Available Due Date: May 25, 2021

 

Notice of Special Interest (NOSI): Using Systems Science Methodologies to Protect and Improve Child and Reproductive Population Health
The purpose of this Notice of Special Interest (NOSI) is to solicit applications to support multi-disciplinary scientific teams proposing research using systems science approaches to address persistent public health challenges. Systems science refers to multi-level methodologies addressing complex behavioral and social phenomena. This initiative encourages applications for both basic and applied research, including methodological and measurement development, with a focus on human behavioral and/or social science. This initiative also seeks to promote interdisciplinary collaboration among health researchers and experts in mathematical modelling.

National Cancer Institute (NCI)
NCI leads and supports research to advance scientific knowledge and help people live longer, healthier lives. NCI has a strong interest in primary prevention and in understanding the development, maintenance and improvement of multiple health behaviors associated with risk of cancer and with health disparities that emerge over the life course. Many of these behaviors have their roots in early development, childhood and adolescence. Because of the long latency of cancer and tracking of health behaviors over the life course, systems science can play a vital role in understanding the development of risk-related behavior over the life course and its consequences of cancer incidence and mortality, as well as modelling positive and negative consequences of programs, policies, and environments aimed at improving child health. NCI is interested in research proposals that address cancer risk factors and cancer incidence and mortality over the life course, including, but not limited to:

• Models that address the complex interactions of diet, physical activity, sedentary behavior, sleep and/or obesity over the trajectory of the life course for children and adolescents.
• Models that address how changes in cancer-related health behaviors in children and over the life course influence population-level cancer incidence and mortality. Diet, physical activity, sedentary behavior, sleep, smoking, alcohol use and sun-related behavior are examples of cancer risk-related behaviors that may arise in children and adolescents.
• Models that address specific programs and policies, such as HPV vaccination, obesity prevention and their cancer-related consequences. Such models could explore how to optimize vaccination delivery and remediation of vaccine program failures as well as estimate long term effects on cancer incidence of primary prevention over the life course.
• The above and other modelling efforts are encouraged to explore disparities and interactions between interventions and at-risk populations to better understand consequences of environments, programs and policies relevant to children and youth for health disparities as well as potential unintended consequences such as inadvertent increases in disparities over time.

Proposals should explicitly address the complex relationships between demographic, social, and environmental determinants of cancer-related health behaviors and physiological characteristics such as obesity. NCI is interested in models of diverse cancer risk-factors, but will give low priority to grants making little or no effort to link their results to population level cancer incidence and mortality.

First Available Due Date: June 5, 2021